Publications by authors named "C N Rautenberg"
The aim of our study was to analyze the potential survival benefit associated with HSCT according to clinico-biological scores which incorporate molecular data (MIPSS70 and MIPSS70+V2) to facilitate decision-making in this context. One transplant (n=241) and one non-transplant cohorts (n=239) were used to test the hypothesis that PMF patients with higher risk molecular score benefit from HSCT. A weighted propensity score was applied to balance confounding factors with the transplanted cohort as reference.
View Article and Find Full Text PDFArticle Synopsis
- Acute and chronic graft-versus-host disease (GvHD) are serious complications that can occur after allogeneic hematopoietic cell transplantation (alloHCT), and anti-T-lymphocyte globulin (ATLG) is commonly used to help prevent these issues.
- A study involving 707 patients with myelofibrosis showed that those who received ATLG had significantly lower rates of acute GvHD (30%) compared to those who did not receive ATLG (56%) and also showed lower rates of severe chronic GvHD.
- Overall, ATLG treatment was associated with better outcomes in terms of GvHD-free and relapse-free survival (GRFS) at six years (45% for AT
Purpose: Acute myeloid leukemia (AML) is a disease of older patients. Progress in allogeneic hematopoietic cell transplantation (allo-HCT) allowed the delivery of allo-HCT to older patients. We assessed changes over time in transplant characteristics and outcomes in patients with AML ages 65 years and above.
View Article and Find Full Text PDFArticle Synopsis
- Splenomegaly is a key issue in patients with myelofibrosis, particularly influencing outcomes after allogeneic hematopoietic cell transplantation (HCT), where it is linked to graft failure.
- A study involving 59 patients demonstrated that splenic irradiation prior to HCT resulted in significant and rapid reductions in spleen size for 97% of participants, with the median decrease being 5.0 cm.
- Overall survival rate at three years was 62%, and splenic irradiation was associated with a lower relapse rate compared to standard HCT approaches, indicating its potential as a beneficial treatment option post-JAK inhibitor failure.
Background: Oral leukoplakia (OL) is an unfavorable oral disease often resistant to therapy. To this end, cold physical plasma technology was explored as a novel therapeutic agent in an experimental setup.
Methods: Biopsies with a diameter of 3 mm were obtained from non-diseased and OL tissues.